Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02097810
Title Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)
Acronym STARTRK-1
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UC Irvine Medical Center Orange California 92868 United States Details
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center San Francisco California 94158 United States Details
University Of Colorado Aurora Colorado 80045 United States Details
Georgetown University Medical Center Washington District of Columbia 20007 United States Details
Florida Cancer Specialists - Sarasota Sarasota Florida 34232 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Tennessee Oncology Nashville Tennessee 37203 United States Details
University of Texas M.D. Anderson Cancer Center Houston Texas 77030 United States Details
Samsung Medical Center Seoul 06531 Korea, Republic of Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field